Dr. April Armstrong reviews the mechanism of action for VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
Topics Covered:
Explore Related Resources:
Clinical Case Updates in Psoriasis Using Topical Tapinarof 1%
Topical Management of Plaque Psoriasis—A Review and Case Study
Important Safety Information
Indication: VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
Adverse Events: The most common adverse reactions (incidence ≥ 1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
For prescribing information, see below or visit https://www.vtama.com/PI/
For important safety information visit https://www.vtama.com/
© 2023 Dermavant Sciences, Inc. All Rights Reserved. All trademarks are the property of Dermavant Sciences, GmbH.
